A number of other research analysts also recently commented on AZN. Argus initiated coverage on shares of Astrazeneca PLC in a research report on Tuesday, July 12th. They issued a hold rating for the company. Bank of America Corp. reissued a buy rating and issued a $36.65 price objective on shares of Astrazeneca PLC in a research report on Monday, July 18th. Beaufort Securities reissued a hold rating on shares of Astrazeneca PLC in a research report on Tuesday, July 19th. Shore Capital reissued a hold rating on shares of Astrazeneca PLC in a research report on Wednesday, July 20th. Finally, TheStreet raised shares of Astrazeneca PLC from a hold rating to a buy rating in a research report on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Astrazeneca PLC currently has a consensus rating of Hold and an average target price of $37.61.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 27.68 on Monday. The company has a market cap of $70.03 billion, a PE ratio of 31.63 and a beta of 0.83. The company has a 50-day moving average of $30.74 and a 200-day moving average of $30.85. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 10th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company earned $5.70 billion during the quarter, compared to the consensus estimate of $5.95 billion. During the same quarter last year, the firm posted $1.03 EPS. The company’s quarterly revenue was down 2.6% on a year-over-year basis. Equities analysts forecast that Astrazeneca PLC will post $2.99 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. NEXT Financial Group Inc raised its stake in Astrazeneca PLC by 8.8% in the second quarter. NEXT Financial Group Inc now owns 6,305 shares of the company’s stock valued at $190,000 after buying an additional 509 shares during the period. New England Research & Management Inc. acquired a new stake in shares of Astrazeneca PLC during the second quarter valued at approximately $777,000. Integrated Investment Consultants LLC raised its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the last quarter. First Financial Bank N.A. Trust Division raised its stake in shares of Astrazeneca PLC by 7.3% in the second quarter. First Financial Bank N.A. Trust Division now owns 7,787 shares of the company’s stock valued at $235,000 after buying an additional 530 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Astrazeneca PLC by 565.2% in the second quarter. BNP Paribas Arbitrage SA now owns 38,857 shares of the company’s stock valued at $1,173,000 after buying an additional 33,016 shares during the last quarter. 11.35% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.